Table 2 Basic information of included patients from our hospital diagnosed in 2003–2019
From: Comparison of metastasis between early-onset and late-onset gastric signet ring cell carcinoma
Variables | Total | Early-onset GSRCC | Late-onset GSRCC | P value |
|---|---|---|---|---|
Total | 403 | 54 | 349 | |
Sex | 0.000 | |||
Male | 259 (64.27%) | 22 (40.74%) | 237 (67.91%) | |
Female | 144 (35.73%) | 32 (59.25%) | 112 (32.09%) | |
Hypertension | 0.121 | |||
No | 353 (87.59%) | 51 (94.44%) | 302 (86.53%) | |
Yes | 50 (12.41%) | 3 (5.56%) | 47 (13.47%) | |
Diabetes | 0.028 | |||
No | 363 (90.07%) | 53 (98.15%) | 310 (88.82%) | |
Yes | 40 (9.93%) | 1 (1.85%) | 39 (11.17%) | |
Smoke | 0.079 | |||
Never | 288 (71.46%) | 44 (81.48%) | 244 (69.91%) | |
Yes | 115 (28.54%) | 10 (18.51%) | 105 (30.09%) | |
Primary site | 0.237 | |||
Cardia | 9 (2.23%) | 1 (1.85%) | 8 (2.29%) | |
Fundus | 8 (1.99%) | 1 (1.85%) | 7 (2%) | |
Antrum | 251 (62.28%) | 29 (53.7%) | 222 (63.61%) | |
Body | 99 (24.57%) | 20 (37.04%) | 79 (22.64%) | |
Overlappping/NOS | 36 (8.93%0 | 3 (5.56%) | 33 (9.46%) | |
T stage | 0.79 | |||
T1 | 69 (17.12%) | 10 (18.51%) | 59 (16.91%) | |
T2 | 55 (13.65%) | 5 (9.26%) | 50 (14.33%) | |
T3 | 52 (12.9%) | 7 (12.96%) | 45 (12.89%) | |
T4 | 227 (56.33%) | 32 (59.25%) | 195 (55.87%) | |
N stage | 0.997 | |||
N0 | 139 (34.49%) | 18 (33.33%) | 121 (34.67%) | |
N1 | 60 (14.89%) | 8 (14.81%) | 52 (14.89%) | |
N2 | 93 (23.08%) | 13 (24.07%) | 80 (22.92%) | |
N3 | 111 (27.54%) | 15 (27.78%) | 96 (27.51%) | |
M stage | 0.036 | |||
M0 | 360 (89.33%) | 43 (79.63%) | 317 (90.83%) | |
M1 | 43 (10.67%) | 11 (20.37%) | 32 (9.17%) | |
Lesion classification | 0.064 | |||
Infiltration type | 20 (4.96%) | 7 (12.96%) | 17 (4.87%) | |
Ulcerative type | 53 (13.15%) | 40 (74.07%) | 286 (81.95%) | |
Protuberant type | 326 (80.89%) | 7 (12.96%) | 46 (13.18%) | |
Lymphatic vessel invasion | 0.023 | |||
No | 185 (45.91%) | 17 (31.48%) | 168 (48.14%) | |
Yes | 218 (54.09%) | 37 (68.52%) | 181(51.86%) | |
Tumor size | 0.562 | |||
≤ 2 cm | 77 (19.11%) | 12 (15.22%) | 65 (18.62%) | |
≤ 5 cm | 150 (37.22%) | 22 (40.74%) | 128 (36.68%) | |
> 5 cm | 176 (43.67%) | 20 (37.04) | 156 (44.7%) | |
Examined LNs | 0.924 | |||
≤ 16 | 58 (14.39%) | 8 (14.81%) | 50 (14.33%) | |
> 16 | 345 (85.61%) | 46 (85.19%) | 299 (85.67%) | |
Chemotherapy | 0.017 | |||
No | 273 (67.74%) | 29 (53.7%) | 244 (69.91%) | |
Yes | 130 (32.26%) | 25 (46.3%) | 105 (30.09%) | |
Methods of surgery | 0.383 | |||
Conditional surgery | 33 (8.19%) | 5 (9.26%) | 28 (8.02%) | |
Laparoscopic surgery | 346 (85.86%) | 48 (88.89%) | 298 (85.39%) | |
Robotic surgery | 24 (5.96%) | 1 (1.85%) | 23 (6.59%) |